Skip to content

Study · Randomized controlled trial · n = 22 · 2018

5 results

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study.

Benamouzig R, Benallaoua M, Saurin JC, Boubaya M, Cellier C, Laugier R, Vincent M, Boustière C, Gincul R, Samaha E, Grandval P, Aparicio T and 6 more

Show all authors

Airinei G, Bejou B, Bon C, Raynaud JJ, Levy V, Sautereau D

Therapeutic advances in gastroenterology16 Feb 2018Cited by 11 (Europe PMC)

PMID29479375 (opens in a new tab)PMCIDPMC5818089 (opens in a new tab)DOI10.1177/1756283x18756260 (opens in a new tab)PepBankPUB-29479375
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In this double-blinded noncomparative randomized phase II study in patients with refractory gastrointestinal angiodysplasia bleeding, transfusion need during the intervention period was 3 pRBC units (range 0-26) with pasireotide-LAR versus 11.5 (range 0-23) with placebo.

    In plain wordsIn patients with gastrointestinal bleeding, transfusion requirements were numerically lower with pasireotide than placebo.

    Peptide
    Pasireotide
    Outcome
    DecreaseTransfusion requirement
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Transfusion Requirements · Gastrointestinal
    Studied dose
    60 mg every 28 days · 6 monthsAs given in this study (human).

    Measurements

    Transfusion need during the intervention period
    3 pRBC units
    pasireotide-LAR group
    Range of transfusion need during the intervention period
    0 to 26 pRBC units
    pasireotide-LAR group
    Transfusion need during the intervention period
    11.5 pRBC units
    placebo group
    Range of transfusion need during the intervention period
    0 to 23 pRBC units
    placebo group

    Source sentences

    Summary
    The need for transfusion during the intervention period was 3 pRBC units in the pasireotide-LAR group (range 0-26) and 11.5 pRBC units in the placebo group (range 0-23).
    2 context sentences
    Summary · context
    A total of 22 patients with transfusion requirements ⩾6 units of packed red blood cells (pRBCs) during the 6 months prior to inclusion were randomized to receive pasireotide-LAR 60 mg (n = 10) or placebo (n = 12) every 28 days for 6 months.
    Summary · context
    The main objective of the ANGIOPAS phase II double-blinded randomized, noncomparative study was to assess the effectiveness of pasireotide-LAR in reducing transfusion requirements in patients with refractory GIADs bleeding.
  2. 02HumanNon-randomized trialEfficacy outcome

    In refractory gastrointestinal angiodysplasia bleeding, 50% of pasireotide recipients achieved at least a 30% reduction in transfused pRBCs in the ITT analysis.

    In plain wordsIn patients with gastrointestinal bleeding, half of pasireotide recipients achieved the specified transfusion reduction from baseline.

    Peptide
    Pasireotide
    Outcome
    Not applicableTransfusion reduction success, ITT
    Study

    n = 10

    Outcome group
    Transfusion Requirements · Gastrointestinal
    Studied dose
    60 mg every 28 days · 6 monthsAs given in this study (human).

    Measurements

    Transfusion reduction success rate (decrease of at least 30% of transfused pRBCs), ITT
    50%
    pasireotide-LAR arm, ITT analysis

    Source sentences

    Summary
    A 50 and 83% success rate (success defined as a decrease of at least 30% of transfused pRBCs) was observed in the pasireotide-LAR arm in the Intent to Treat (ITT) and per protocol (PP) analysis respectively.
    1 context sentence
    Summary · context
    A total of 22 patients with transfusion requirements ⩾6 units of packed red blood cells (pRBCs) during the 6 months prior to inclusion were randomized to receive pasireotide-LAR 60 mg (n = 10) or placebo (n = 12) every 28 days for 6 months.
  3. 03HumanNon-randomized trialSafety outcome

    In refractory gastrointestinal angiodysplasia bleeding, three pasireotide recipients experienced impaired glycemic control.

    In plain wordsIn patients with gastrointestinal bleeding, three pasireotide recipients had impaired blood sugar control.

    Peptide
    Pasireotide
    Outcome
    Not applicableGlycemic control impairment
    Study

    n = 10

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    60 mg every 28 days · 6 monthsAs given in this study (human).

    Measurements

    Cases with glycemic control impairment
    3 cases
    pasireotide-LAR group

    Source sentences

    Summary
    Overall, three cases with glycemic control impairment were observed in the pasireotide-LAR group including one de novo diabetes.
    1 context sentence
    Summary · context
    A total of 22 patients with transfusion requirements ⩾6 units of packed red blood cells (pRBCs) during the 6 months prior to inclusion were randomized to receive pasireotide-LAR 60 mg (n = 10) or placebo (n = 12) every 28 days for 6 months.
  4. 04HumanNon-randomized trialSafety outcome

    In refractory gastrointestinal angiodysplasia bleeding, one pasireotide recipient developed new diabetes.

    In plain wordsIn patients with gastrointestinal bleeding, one pasireotide recipient developed diabetes.

    Peptide
    Pasireotide
    Outcome
    Not applicableNew diabetes
    Study

    n = 10

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    60 mg every 28 days · 6 monthsAs given in this study (human).

    Measurements

    Cases of de novo diabetes
    1 cases
    pasireotide-LAR group

    Source sentences

    Summary
    Overall, three cases with glycemic control impairment were observed in the pasireotide-LAR group including one de novo diabetes.
    1 context sentence
    Summary · context
    A total of 22 patients with transfusion requirements ⩾6 units of packed red blood cells (pRBCs) during the 6 months prior to inclusion were randomized to receive pasireotide-LAR 60 mg (n = 10) or placebo (n = 12) every 28 days for 6 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In refractory gastrointestinal angiodysplasia bleeding, 83% of pasireotide recipients achieved at least a 30% reduction in transfused pRBCs in the per-protocol analysis.

    In plain wordsIn patients with gastrointestinal bleeding, 83% of the pasireotide per-protocol group achieved the specified transfusion reduction from baseline.

    Peptide
    Pasireotide
    Outcome
    Not applicableTransfusion reduction success, per protocol
    Study

    n: not reported in source

    Outcome group
    Transfusion Requirements · Gastrointestinal
    Studied dose
    60 mg every 28 days · 6 monthsAs given in this study (human).

    Measurements

    Transfusion reduction success rate (decrease of at least 30% of transfused pRBCs), per protocol
    83%
    pasireotide-LAR arm, per-protocol analysis

    Source sentences

    Summary
    A 50 and 83% success rate (success defined as a decrease of at least 30% of transfused pRBCs) was observed in the pasireotide-LAR arm in the Intent to Treat (ITT) and per protocol (PP) analysis respectively.
    1 context sentence
    Summary · context
    A total of 22 patients with transfusion requirements ⩾6 units of packed red blood cells (pRBCs) during the 6 months prior to inclusion were randomized to receive pasireotide-LAR 60 mg (n = 10) or placebo (n = 12) every 28 days for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.